ID/ASP Pharmacist Swedish Medical Center| Pharmacy School: U of Colorado | PGY1: Stanford Health Care | PGY2: Infectious Diseases Duke University Hospital
Back at it again, this time aspiration pneumonia - any thoughts, #IDTwitter ? Managed to get some pharmacist-led literature in here too! This one feels a little light, did I miss anything? @ABsteward
This meta-analysis pools the data from all 3 available RCT on treatment duration for Gram-negative BSI.
7️⃣ days is now SOC for treating uncomplicated BSI!
📚 https://t.co/qpGQAnUJo2 #ShorterIsBetter@ABsteward
NEW in @AnnalsofPharm@LinezoLiz provides insight into the accuracy of open-access, trough-only online calculators in vancomycin AUC calculation.
Conclusion? VancoPK performed the best with a median actual difference = -0.8 (p = NS).
https://t.co/BtMmY790LK
I don't usually tweet at this time unless...
🆕⚡⚡multicenter RCT @CIDJournal
An antibiotic opt-out protocol targeting pts w suspected sepsis resulted in more antibiotic discontinuations, similar DOT when antibiotics were continued, no evidence of harm
https://t.co/5AHEfQNR4F
Help us celebrate our graduating class of pharmacy residents today! 💊🎓👏 We are so proud of you all and excited to see how you go and change the world! #DukeRx
Outgoing and incoming ID residents! So excited for @linezoliz and her next adventure. Looking forward to working with Ethan Brenneman starting . . . next week (where does the time go?)!
【Resistant to Amphotericin B】
Please consider these organisms for breakthrough infections in patients receiving Ambisome!!
Level: Intermediate
Importance: ★★★
#IDTwitter#IDMedEd#IDFellow#TxID#Antifungal
In case you're wondering, the incidence of beta-lactam neurotoxicity isn't 7-23% as some papers cite IMO...it's 2-3% (if that)...this much more closely matches my clinical perspective...Congrats @nataliehaddadrx on the great work!! #TwitteRx#PharmICU
https://t.co/2pC72KDYDb
Back on ID-Onc this week @ColoradoID@CUAnschutz@CUCancerCenter. Great review by my former colleagues @zoeweissMD @JessicaLittleMD on risk of IFI with many of the targeted therapies we use for our heme/onc pts. Table 1 and 2 are💰💸